Goldenberg Ilan, Subirana Isaac, Boyko Valentina, Vila Joan, Elosua Roberto, Permanyer-Miralda Gaieta, Ferreira-González Ignacio, Benderly Michal, Guetta Victor, Behar Shlomo, Marrugat Jaume
Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer, 52621, Israel.
Arch Intern Med. 2010 May 24;170(10):888-95. doi: 10.1001/archinternmed.2010.95.
Clinical trials provide limited information about the outcome of patients with acute coronary syndromes (ACSs) and kidney disease (KD) owing to underrepresentation of this population in most studies.
To evaluate the outcome of patients with non-ST-segment elevation ACS (NSTE-ACS) and KD in a real-world setting, we compared the risk of in-hospital and 30-day mortality by the presence of KD (defined as an estimated glomerular filtration rate <60 mL/min/1.73 m(2)) in 13 141 patients with NSTE-ACS enrolled in 3 multinational ACS registries between 2000 and 2006 as part of the European Public Health Outcome Research and Indicators Collection Project.
Patients with KD (n = 4181) composed 31.8% of the study population and had significantly higher rates of in-hospital (5.4%) and 30-day (7.2%) case fatality compared with patients without KD (1.1% and 1.7%, respectively; P < .001 for both). In multivariate analysis, the presence of KD was independently associated with a significantly higher mortality risk (in-hospital: odds ratio [OR], 2.11; 95% confidence interval [CI], 1.48-3.00; 30-day: OR, 1.95; 95% CI, 1.46-2.61). Patients with KD who underwent coronary angiography experienced a 36% (P = .05) and 40% (P < .001) lower risk of in-hospital and 30-day mortality, respectively, but this high-risk population still exhibited significantly higher case-fatality rates during hospitalization (3.3%) and at 30 days (4.6%) compared with patients without KD who underwent coronary angiography (0.7% and 1.3%, respectively; P < .001 for all).
In a real-world setting, KD was present in approximately one-third of patients with NSTE-ACS and is a powerful independent predictor of subsequent mortality. Patients with NSTE-ACS and KD referred for coronary angiography have a significantly lower risk of death, but this high-risk population continues to exhibit increased mortality rates despite intervention procedures.
由于在大多数研究中该人群的代表性不足,临床试验提供的关于急性冠状动脉综合征(ACS)和肾病(KD)患者预后的信息有限。
为了评估非ST段抬高型ACS(NSTE-ACS)和KD患者在现实世界中的预后,我们比较了2000年至2006年间纳入3个跨国ACS注册研究的13141例NSTE-ACS患者中,KD(定义为估计肾小球滤过率<60 mL/min/1.73 m²)患者与非KD患者的住院及30天死亡率风险。该研究是欧洲公共卫生结局研究与指标收集项目的一部分。
KD患者(n = 4181)占研究人群的31.8%,与非KD患者相比,其住院死亡率(5.4%)和30天死亡率(7.2%)显著更高(非KD患者分别为1.1%和1.7%;两者P均<0.001)。多因素分析显示,KD的存在与显著更高的死亡风险独立相关(住院:比值比[OR],2.11;95%置信区间[CI],1.48 - 3.00;30天:OR,1.95;95% CI,1.46 - 2.61)。接受冠状动脉造影的KD患者住院死亡率和30天死亡率风险分别降低36%(P = 0.05)和40%(P < 0.001),但与接受冠状动脉造影的非KD患者相比,这一高风险人群在住院期间(3.3%)和30天时(4.6%)的病死率仍显著更高(非KD患者分别为0.7%和1.3%;所有P均<0.001)。
在现实世界中,约三分之一的NSTE-ACS患者存在KD,且KD是后续死亡的有力独立预测因素。接受冠状动脉造影的NSTE-ACS和KD患者死亡风险显著降低,但尽管进行了干预措施,这一高风险人群的死亡率仍持续升高。